Switching to Immediate-Release Drugs May Save Billions

The Medicare Part D and Medicaid programs could save a significant amount of money if more patients took immediate-release (IR) medications that require two doses per day instead of extended-release (ER) versions that are taken just once a day, according to a recent study. The cross-sectional study analyzed 20 extended-release drugs with 37 Medicare formulations and 36 Medicaid formulations. Between 2012 and 2017, Medicare Part D and Medicaid could have saved a combined $13.7 billion through a switch from ER to IR formulations. “It’s not a huge difference in terms of patient convenience, but the cost difference is remarkable,” study coauthor Ambarish Pandey, M.D., of the University of Texas Southwestern Medical Center, told Reuters.

© 2021 MMIT

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Experts-EU-Will-Continue-to-Beat-US-on-Biosimilar-Adoption.jpg
September 23

Experts: EU Will Continue to Beat US on Biosimilar Adoption

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Pharma-Industry-Braces-as-Dems-Hash-Out-Drug-Price-Package.jpg
September 23

Pharma Industry Braces as Dems Hash Out Drug Price Package

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Study-Flags-Potential-Benefit-of-Targeted-Medication-Reviews.jpg
September 23

Study Flags Potential Benefit of Targeted Medication Reviews

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today